Proclivity to Explore Locally Advanced Pancreas Cancer Is Not Associated with Surgeon Volume

[1]  J. D'haese,et al.  Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. , 2019, Surgical oncology.

[2]  J. Cameron,et al.  Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. , 2019, Annals of surgery.

[3]  elliot k fishman,et al.  Management of Locally Advanced Pancreatic Cancer , 2019, Annals of surgery.

[4]  J. Cameron,et al.  Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[5]  J. Cameron,et al.  Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. , 2019, Annals of surgery.

[6]  M. Ducreux,et al.  Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study , 2019, BMC Cancer.

[7]  elliot k fishman,et al.  Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies , 2019, Cancers.

[8]  R. J. Haas,et al.  Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation , 2019, The British journal of surgery.

[9]  W. Harmsen,et al.  Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. , 2019, Annals of surgery.

[10]  M. Makary,et al.  Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? , 2018, Annals of surgery.

[11]  Hai Hu,et al.  Predictors of Resectability and Survival in Patients with Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment with FOLFIRINOX. , 2017, Annals of surgery.

[12]  E. Fishman,et al.  Pancreaticoduodenectomy with venous resection and reconstruction: current surgical techniques and associated postoperative imaging findings , 2017, Abdominal Radiology.

[13]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  F. Rocha,et al.  Surgical strategies and novel therapies for locally advanced pancreatic cancer , 2017, Journal of surgical oncology.

[15]  Joanna Chikwe,et al.  Relation of Mitral Valve Surgery Volume to Repair Rate, Durability, and Survival. , 2017, Journal of the American College of Cardiology.

[16]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[17]  D. Urbach.  Pledging to Eliminate Low-Volume Surgery. , 2015, The New England journal of medicine.

[18]  M. Weiss,et al.  Surgery for oligometastasis of pancreatic cancer. , 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[19]  S. Hendren,et al.  Surgical Referral for Colorectal Liver Metastases: A Population-Based Survey , 2015, Annals of Surgical Oncology.

[20]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[21]  K. Lillemoe,et al.  Does regional variation impact decision-making in the management and palliation of pancreatic head adenocarcinoma? Results from an international survey. , 2014, Canadian journal of surgery. Journal canadien de chirurgie.

[22]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[23]  E. Fishman,et al.  Recent progress in pancreatic cancer , 2013, CA: a cancer journal for clinicians.

[24]  Justin B. Dimick,et al.  Hospital Volume and Operative Mortality in the Modern Era , 2013, Annals of surgery.

[25]  D. Gouma,et al.  Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality , 2012, The British journal of surgery.

[26]  G. Abel,et al.  Increasing response rates from physicians in oncology research: a structured literature review and data from a recent physician survey , 2012, British Journal of Cancer.

[27]  K. Lillemoe,et al.  Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experience. , 2010, Archives of surgery.

[28]  J. Tseng,et al.  Surgeon Volume Impacts Hospital Mortality for Pancreatic Resection , 2009, Annals of surgery.

[29]  M. Choti,et al.  The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. , 2009, Journal of the American College of Surgeons.

[30]  N. Ahuja,et al.  What constitutes a "high-volume" hospital for pancreatic resection? , 2008, Journal of the American College of Surgeons.

[31]  Kathryn E. McGoldrick,et al.  Surgeon Volume and Operative Mortality in the United States , 2004 .

[32]  Robert E Harbaugh,et al.  Surgeon Volume and Operative Mortality in the United States. , 2004, Neurosurgery.

[33]  J. Birkmeyer,et al.  Hospital volume and surgical mortality in the United States. , 2002, The New England journal of medicine.

[34]  J. Tielsch,et al.  The Effects of Regionalization on Cost and Outcome for One General High‐Risk Surgical Procedure , 1995, Annals of surgery.

[35]  J H Allema,et al.  Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head , 1994, The British journal of surgery.

[36]  Jeffrey W. Clark,et al.  "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer." , 2017, Annals of surgery.